Nova Mentis Life Science (Nova Mentis Life Science) Total Liabilities : $0.74 Mil (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Nova Mentis Life Science Total Liabilities?

Nova Mentis Life Science's Total Liabilities for the quarter that ended in Mar. 2024 was $0.74 Mil.

Nova Mentis Life Science's quarterly Total Liabilities increased from Mar. 2023 ($0.25 Mil) to Sep. 2023 ($0.48 Mil) and increased from Sep. 2023 ($0.48 Mil) to Mar. 2024 ($0.74 Mil).

Nova Mentis Life Science's annual Total Liabilities increased from Dec. 2020 ($0.30 Mil) to Dec. 2021 ($0.33 Mil) but then declined from Dec. 2021 ($0.33 Mil) to Dec. 2022 ($0.19 Mil).

Nova Mentis Life Science Total Liabilities Historical Data

The historical data trend for Nova Mentis Life Science's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nova Mentis Life Science Total Liabilities Chart

Nova Mentis Life Science Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Liabilities

Get a 7-Day Free Trial

0.23

0.25

0.30

0.33

0.19

Nova Mentis Life Science Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Mar24
Total Liabilities	Get a 7-Day Free Trial															0.17	0.19	0.25	0.48	0.74

Nova Mentis Life Science Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Nova Mentis Life Science's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.188	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	0.19

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	0.219	-	0.03
	=	0.19

Nova Mentis Life Science's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.735	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	0.74

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	0.03	-	-0.706
	=	0.74

Nova Mentis Life Science Total Liabilities Related Terms

Thank you for viewing the detailed overview of Nova Mentis Life Science's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Nova Mentis Life Science (Nova Mentis Life Science) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nova Mentis Life Science Corp (OTCPK:NMLSF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

HN3Q:Germany NOVA:Canada

Address

700-838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6

Website

https://www.novamentis.ca

Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.

Nova Mentis Life Science (Nova Mentis Life Science) Headlines

From GuruFocus

Healthcare Breakthroughs: NVAX, MITO, LMLLF, NMLSF; Life Sciences Leaders Report Latest Advances in Vaccines, Novel Therapeutics for Autism, Neurodegenerative, Oncology, and Glaucoma

By GuruFocusNews GuruFocusNews • 06-28-2022

BioMed Stocks On the Move: Nova Mentis, PolarityTE, Veru, and PharmaDrug; Life Sciences Leaders Report Latest Advances in Regenerative Tissue Technology, Novel Therapeutics for Oncology, COVID, Glaucoma, and Autism

By GuruFocusNews GuruFocusNews • 06-22-2022

Nova Mentis and Mycrodose Therapeutics Announce Major Milestone with Transdermal Technology for Fragile X Syndrome Clinical Program

By PRNewswire PRNewswire • 12-16-2021

By GuruFocusNews GuruFocusNews • 05-13-2022

By GuruFocusNews GuruFocusNews • 06-12-2022

By GuruFocusNews GuruFocusNews • 05-23-2022

By GuruFocusNews GuruFocusNews • 07-02-2022

Healthcare Breakthroughs: IDRA, NMLSF, LMLLF, BBI; Life Sciences Leaders Report Latest Advances in Novel Therapeutics for Autism, Oncology, Autoimmune Diseases, and Glaucoma

By GuruFocusNews GuruFocusNews • 05-17-2022

Healthcare Breakthroughs: NVAX, MITO, LMLLF, NMLSF; Life Sciences Leaders Report Latest Advances in Vaccines, Novel Therapeutics for Autism, Neurodegenerative, Oncology, and Glaucoma

By GuruFocusNews GuruFocusNews • 06-18-2022

Healthcare Breakthroughs: IDRA, NMLSF, LMLLF, BBI; Life Sciences Leaders Report Latest Advances in Novel Therapeutics for Autism, Oncology, Autoimmune Diseases, and Glaucoma

By GuruFocusNews GuruFocusNews • 05-27-2022